Topic summary

Why a glucagon receptor agonist in a weight-loss compound is not a contradiction

Compounds › Retatrutide retatrutide preprint randomised trial effect size Solved

This is a generated summary. It shows the 7 most-liked posts from a topic of 48, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

c.wijnbergTL2Member7 Jun 2026#1

The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it.

I would like to disagree carefully with the settled view on glucagon receptor agonist, and I would like to be argued out of it if the disagreement is bad.

The disagreement is about one step, not about the conclusion. If the step holds I withdraw it entirely.

27 likes 2mo

s.grimaldiTL2 Solution17 Jun 2026#7

Triple agonism at GLP-1, GIP and glucagon receptors is the defining feature and the glucagon limb is the one people find counter-intuitive. It raises energy expenditure and promotes hepatic fat oxidation, and the incretin limbs offset the glycaemic consequence.

7 likes 1mo

dr.villanuevaTL3Physician18 Jun 2026#8

sourced_claims, post #6: The arithmetic in post #3 is right; the assumption feeding it is the part to check. Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established… Go to post

No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.

29 likes in reply to #6 1mo

b.demirTL219 Jun 2026#9

Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make claims about safety profile is using the trial for a purpose it was not designed for.

Nothing above should be read as advice about what anyone else should do.

28 likes 1mo

k.fonsecaTL224 Jun 2026#13

On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.

A guess, clearly labelled as one.

33 likes 1mo

BramleyTL2Member6 Jul 2026#25

Same experience here, different supplier, so it is at least not unique to one of them.

29 likes 22d

n.bridgewaterTL2Member26 Jul 2026#48

v.milanovi, post #46: Post #45 is the version of this I will quote in future. One addition. Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make claims about safety profile is using the trial for a purpose it was not designed for. Go to post

Bookmarking this. I will come back when I have something worth adding.

32 likes in reply to #46 2d

Read the full topic (48 posts)

This topic was referenced in

Retatrutide mass and identity: what a report should showCompounds › Retatrutide · 27 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…	+115	125	30k	2y
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide retatrutide randomised trial effect size preprint Solved Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. A methods question rather than a substantive…	+10	14	8.4k	16h
Retatrutide mass and identity: what a report should show Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. The question about retatrutide mass and identity that I actually…	+22	27	872	22h
How to read a phase 2 result without treating it as a phase 3 result — what changed since Compounds › Retatrutide TRIUMPH programme randomised trial preprint Solved Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Putting the numbers in the first post, because a question…	+25	35	568	6mo
Follow-up: The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. A follow-up question about retatrutide phase 2 obesity paper that I did not know to…	+19	23	16k	2d

Related topics — sharing the tags retatrutide, preprint, randomised trial

Topic	Participants	Replies	Views	Activity
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. I would like to know…	+109	124	31k	10mo
[2026 update] Correlation in a self-tracked dataset: what it can support Research Methods › Statistics number needed to treat effect size worked example heterogeneity Posting this under the heading it deserves: Correlation in a self-tracked dataset: what it can support Everything below is what sits behind that. Posting a small dataset on Correlation. It is mine, it is…		2	31k	6h
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…	+114	120	1.4k	10mo
Comparing the STEP programme populations: who was actually enrolled Compounds › Semaglutide SELECT trial STEP programme semaglutide effect size Solved Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…		2	7.5k	2mo
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? Compounds › Semaglutide randomised trial type 2 diabetes STEP programme effect size Solved Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question…	+58	62	49k	20mo